Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. (14th July 2021) - Van Voorhees, A.S.; Stein Gold, L.; Lebwohl, M.; Strober, B.; Sofen, H.; Papp, K.; Bagel, J.; Zhang, Z.; Paris, M.; Wang, Y.